FDA vs Health Canada PMS Requirements: Side-by-Side Comparison for Dual-Market Manufacturers

Why Compare FDA and Health Canada PMS?

Many medical device manufacturers sell in both the United States and Canada. While the Medical Device Single Audit Program (MDSAP) provides some harmonization of quality system requirements, significant differences remain in post-market surveillance obligations between the two markets. Understanding where requirements overlap and where they diverge is essential for dual-market compliance.

This guide provides a side-by-side comparison of FDA and Health Canada post-market surveillance requirements, helping RA/QA professionals design a single PMS system that satisfies both regulators.

Side-by-Side Comparison

Key Differences

• Reporting speed: Health Canada requires preliminary reports within 10 calendar days — three times faster than FDA's 30-day deadline. Manufacturers selling in both markets should use the 10-day timeline as their internal standard.
• Audit model: FDA conducts direct inspections through its own investigators. Health Canada relies on MDSAP third-party audits. This means the audit experience differs significantly — MDSAP audits are scheduled and systematic, while FDA inspections can be unannounced.
• Trend analysis: MDSAP Chapter 5 explicitly requires documented trend analysis. FDA recommends it through guidance but does not mandate it under current QSR. However, QMSR 2026 will bring FDA closer to the MDSAP standard.
• Device classification: Health Canada classifies devices into four classes (I-IV) while FDA uses three (I-III). Class IV in Canada roughly corresponds to Class III in the U.S., but the boundaries don't align exactly.
• Recall authority: Both agencies can order recalls, but Health Canada exercises this power more readily under section 21.3 of the Food and Drugs Act. FDA has traditionally relied more on voluntary recalls.

Key Similarities

• Both require complaint handling systems with documented investigation and reportability assessment
• Both require assessment of whether each adverse event meets reporting criteria
• MDSAP harmonizes quality system requirements across both markets using ISO 13485 as the foundation
• ISO 14971 risk management underpins post-market surveillance requirements in both jurisdictions
• Both expect documented evidence of systematic monitoring — not just reactive complaint handling
• Both agencies publish public databases that manufacturers should monitor for signals related to their devices

Dual-Market Compliance Strategy

For manufacturers selling in both the U.S. and Canada, the most efficient approach is to build a single PMS system that satisfies the stricter of the two requirements:

1. Use the 10-day reporting timeline as your internal standard. This meets Health Canada's 10-day preliminary requirement and provides comfortable margin for FDA's 30-day deadline.
2. Maintain MDSAP certification. It satisfies Health Canada's quality system requirement and aligns closely with QMSR for FDA. When QMSR takes effect in February 2026, MDSAP-certified manufacturers will have minimal additional work.
3. Monitor regulatory signals from both markets simultaneously. FDA enforcement actions, 510(k) clearances, PMA approvals, and recalls from both jurisdictions should feed into a single review queue.
4. Implement documented trend analysis. MDSAP requires it now, and QMSR 2026 will make it expected for FDA as well. Building this capability early avoids compliance gaps.
5. Document review decisions with substantive rationale. Both FDA inspectors and MDSAP auditors expect more than "reviewed — no action." Each PMS signal review should include the reviewer's reasoning, the risk assessment, and any follow-up actions.

How TrueMedDevice Monitors Both Markets

TrueMedDevice aggregates 548,000+ regulatory records from 7 official sources across both markets into a single searchable database with automated relevance matching:

• 4 FDA sources: Enforcement actions (38,017), 510(k) clearances (174,008), PMA approvals (54,186), Device recalls (57,067) — 323,278 total
• 3 Health Canada sources: Recalls (10,301), MDALL licences (72,640), MDL device listings (142,250) — 225,191 total

The platform matches signals to your device profile, scores relevance (High / Medium / Low), and generates audit-ready evidence packs with full citations and traceability — satisfying both FDA and MDSAP documentation expectations.

• Take the free PMS Gap Assessment — Evaluate your compliance across 30 requirements covering both FDA and Health Canada.
• Try a free demo — See real signals from both markets matched to your device in under 3 minutes.
• View pricing — Single-market monitoring from $199/mo, dual-market from $259/mo.